Your Health, We Care
selpercatinib is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
selpercatinib is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1)rearrangement.
from FDA，2024.06
Serpatinib is a new type of therapeutic drug that has attracted much attention i···【more】
Release date：2024-12-24Recommended：166
Serpatinib is an innovative drug that is attracting increasing attention for its···【more】
Release date：2024-12-24Recommended：165
Serpatinib, a new type of drug, is increasingly used in the medical field. Its i···【more】
Release date：2024-12-23Recommended：159
Selpercatinib is a targeted therapy drug that is mainly used to inhibit cancer c···【more】
Release date：2024-08-15Recommended：231
As a targeted drug targeting RET mutations, Selpercatinib can block the signalin···【more】
Release date：2024-08-15Recommended：192
Serpatinib interferes with the growth signal of cancer cells by selectively inhi···【more】
Release date：2024-08-15Recommended：267
